SlideShare a Scribd company logo
 
AF and OPCABs in our experience  Chokchai Suwanakijboriharn Bangkok Heart Hospital Thailand
OBJECTIVE : ,[object Object],[object Object]
METHODS : ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
DERMOGRAPHY *0.000 232(76%) 72(28%) Age>70 *0.000  61.6(±10.4) 65.9(± 9.9) Age(mean/SD)  NS 197(22%) 35(21%) female NS 728(78%) 135(79%) Male 925 170 Overall  CASE P value NO AF AF Parameter
Coronary risk factors NS 27(3%) 1(0.6%) Morbid obesity NS 429(46%) 74(46%) Diabetes  NS 596(64%) 119(70%) Hypertension  Coronary risk factors P value NO AF AF
Comorbid NS 37(4%) 9(5%) CVA NS 71(8%) 17(10%) COPD NS 22(2%) 3(2%) PVD NS 34(4%) 9(5%) Renal failure  Comorbid  P value NO AF AF
Risk factors 0.074 67(7%) 6(4%) Cardiogenic shock 0.017 65(7%) 18(11%) Prior PCI Cardiac profile NS 376(42%) 74(45%) Unstable angina NS 332(36%) 63(37%) Left main  *0.006 166(18%) 46(27%) CHF NS 268(29%) 46(27%) HX of MI P value NO AF AF
Operative factors NS 175(19%) 40(24%) LVEF<40% NS 879(95%) 157(92%) Elective  NS 52.5±15.0 50.3±16.1 EF NS 29(3%) 7(4%) Emergency  NS 17(2%) 6(4%) Urgency  NS 33(4%) 2(1%) Re Do case NS 892(96%) 168(99%) 1 st  operation P value NO AF AF
Operative factors NS 244(26%) 48(28%) RGA used NS 112(12%) 13(8%) RIMA used NS 270(29%) 47(28%) SVG used NS 95(10%) 19(11%) RRA used NS 644(70%) 117(69%) LRA used NS 870(94%) 158(93%) LIMA used NS 4.17±1.34 4.11±1.38 Graft/patient P value NO AF AF
Postoperative results NS 0 1(0.6%) Periop MI NS 5.32±17.3 8.11±28.9 Intubation time  (Hr) NS 6(0.6%) 0 Conversion rate NS 4.85±1.29 4.99±1.17 Skin to skin NS 139(15%) 29(17%) IABP P value NO AF AF
Postoperative result *0.019 21(2%) 10(6%) Prolong ventilation (Hr) NS 15(2%) 3(2%) Re op bleeding *0.038 8(1%) 5(3%) Postop ARF , dialysis require  NS 2(0.2%) 1(0.6%) Permanent stroke P value NO AF AF Parameter
Postoperative results NS 43(4.6%) 5(2.9%) Operative mortality *0.004 10.81±9.58 13.65±10.43 LOS *0.001 6(0.6%) 7(4%) Pneumonia  NS 1(0.1%) 0 Deep sternal wound infection NS 44(5%) 8(5%) 30 day readmission after procedure  P value NO AF AF Parameter
[object Object],[object Object],[object Object],[object Object]
Out come between 2 group *0.038 8(1%) 5(3%) Postop ARF , dialysis require  0.017 65(7%) 18(11%) Prior PCI *0.006 166(18%) 46(27%) CHF *0.000 232(76%) 72(28%) Age>70 *0.000  61.6(±10.4) 65.9(± 9.9) Age(mean/SD)  P value NO AF AF Parameter
Out come between 2 group P value NO AF AF Parameter  *0.004 10.81±9.58 13.65±10.43 LOS *0.001 6(0.6%) 7(4%) Pneumonia  *0.019 21(2%) 10(6%) Prolong ventilation (Hr)
RISK FACTORS INFLUENCING OUTCOME 0.048 1.057 – 3.299 1.867 0.017 Prior PCI or balloon  0.003 1.465-16.485 4.913 0.001 Pneumonia  0.001 1.335 – 3.363 2.119 0.006 CHF 0.003 0.108-0.703  0.275 0.074 Cardiogenic shock 0.000 1.483-3.025 2.118 0.000 Age>70 Multivariate  p value 95% confidence interval Relative risk Univariate p  value
Thank You…

More Related Content

What's hot

Dzavik V - AIMRADIAL 2014 - Rotablator and radial approach
Dzavik V - AIMRADIAL 2014 - Rotablator and radial approachDzavik V - AIMRADIAL 2014 - Rotablator and radial approach
Dzavik V - AIMRADIAL 2014 - Rotablator and radial approach
International Chair on Interventional Cardiology and Transradial Approach
 
PCI & AimRadial 2018 | Experience with Left Main PCI by Radial Access - Zsolt...
PCI & AimRadial 2018 | Experience with Left Main PCI by Radial Access - Zsolt...PCI & AimRadial 2018 | Experience with Left Main PCI by Radial Access - Zsolt...
PCI & AimRadial 2018 | Experience with Left Main PCI by Radial Access - Zsolt...
International Chair on Interventional Cardiology and Transradial Approach
 
Nolan J - AIMRADIAL 2014 - Radialists and femoral access
Nolan J - AIMRADIAL 2014 - Radialists and femoral accessNolan J - AIMRADIAL 2014 - Radialists and femoral access
Nolan J - AIMRADIAL 2014 - Radialists and femoral access
International Chair on Interventional Cardiology and Transradial Approach
 
Nolan J - AIMRADIAL 2014 - Heparin is better
Nolan J - AIMRADIAL 2014 - Heparin is betterNolan J - AIMRADIAL 2014 - Heparin is better
Gilchrist IC 201305
Gilchrist IC 201305Gilchrist IC 201305
Dzavik V - AIMRADIAL 2014 - Radial artery size
Dzavik V - AIMRADIAL 2014 - Radial artery sizeDzavik V - AIMRADIAL 2014 - Radial artery size
CTO and low ejection fraction
CTO and low ejection fraction CTO and low ejection fraction
CTO and low ejection fraction
Euro CTO Club
 
Jolly SS et al
Jolly SS et alJolly SS et al
Acs ami update-win program - scai 2010
Acs   ami update-win program - scai 2010Acs   ami update-win program - scai 2010
Acs ami update-win program - scai 2010Trimed Media Group
 
Jolly S - Radiation exposure and transradial - 201507
Jolly S - Radiation exposure and transradial - 201507Jolly S - Radiation exposure and transradial - 201507
Jolly S - Radiation exposure and transradial - 201507
International Chair on Interventional Cardiology and Transradial Approach
 
Mamas M - AIMRADIAL 2014 - Cardiogenic shock
Mamas M - AIMRADIAL 2014 - Cardiogenic shockMamas M - AIMRADIAL 2014 - Cardiogenic shock
10:50 Werner - Identifying the patients that benefit from CTO PCI
10:50 Werner -  Identifying the patients that benefit from CTO PCI10:50 Werner -  Identifying the patients that benefit from CTO PCI
10:50 Werner - Identifying the patients that benefit from CTO PCI
Euro CTO Club
 
12 Valgimigli aimradial20170921 MATRIX program
12 Valgimigli aimradial20170921 MATRIX program12 Valgimigli aimradial20170921 MATRIX program
Roberts J - AIMRADIAL 2015 - Ultrasound guidance
Roberts J - AIMRADIAL 2015 - Ultrasound guidanceRoberts J - AIMRADIAL 2015 - Ultrasound guidance
Roberts J - AIMRADIAL 2015 - Ultrasound guidance
International Chair on Interventional Cardiology and Transradial Approach
 
6_OP_Interventional_Cardiology_Report
6_OP_Interventional_Cardiology_Report6_OP_Interventional_Cardiology_Report
6_OP_Interventional_Cardiology_ReportEd Bartholomew
 
Statin trials
Statin trials Statin trials
Statin trials
Saitej Reddy
 
Louvard Y - Start radial and advance the skill
Louvard Y - Start radial and advance the skillLouvard Y - Start radial and advance the skill
Anaesth audit
Anaesth auditAnaesth audit

What's hot (20)

Dzavik V - AIMRADIAL 2014 - Rotablator and radial approach
Dzavik V - AIMRADIAL 2014 - Rotablator and radial approachDzavik V - AIMRADIAL 2014 - Rotablator and radial approach
Dzavik V - AIMRADIAL 2014 - Rotablator and radial approach
 
PCI & AimRadial 2018 | Experience with Left Main PCI by Radial Access - Zsolt...
PCI & AimRadial 2018 | Experience with Left Main PCI by Radial Access - Zsolt...PCI & AimRadial 2018 | Experience with Left Main PCI by Radial Access - Zsolt...
PCI & AimRadial 2018 | Experience with Left Main PCI by Radial Access - Zsolt...
 
Nolan J - AIMRADIAL 2014 - Radialists and femoral access
Nolan J - AIMRADIAL 2014 - Radialists and femoral accessNolan J - AIMRADIAL 2014 - Radialists and femoral access
Nolan J - AIMRADIAL 2014 - Radialists and femoral access
 
Nolan J - AIMRADIAL 2014 - Heparin is better
Nolan J - AIMRADIAL 2014 - Heparin is betterNolan J - AIMRADIAL 2014 - Heparin is better
Nolan J - AIMRADIAL 2014 - Heparin is better
 
Gilchrist IC 201305
Gilchrist IC 201305Gilchrist IC 201305
Gilchrist IC 201305
 
Dzavik V - AIMRADIAL 2014 - Radial artery size
Dzavik V - AIMRADIAL 2014 - Radial artery sizeDzavik V - AIMRADIAL 2014 - Radial artery size
Dzavik V - AIMRADIAL 2014 - Radial artery size
 
CTO and low ejection fraction
CTO and low ejection fraction CTO and low ejection fraction
CTO and low ejection fraction
 
Jolly SS et al
Jolly SS et alJolly SS et al
Jolly SS et al
 
Acs ami update-win program - scai 2010
Acs   ami update-win program - scai 2010Acs   ami update-win program - scai 2010
Acs ami update-win program - scai 2010
 
Jolly S - Radiation exposure and transradial - 201507
Jolly S - Radiation exposure and transradial - 201507Jolly S - Radiation exposure and transradial - 201507
Jolly S - Radiation exposure and transradial - 201507
 
Mamas M - AIMRADIAL 2014 - Cardiogenic shock
Mamas M - AIMRADIAL 2014 - Cardiogenic shockMamas M - AIMRADIAL 2014 - Cardiogenic shock
Mamas M - AIMRADIAL 2014 - Cardiogenic shock
 
10:50 Werner - Identifying the patients that benefit from CTO PCI
10:50 Werner -  Identifying the patients that benefit from CTO PCI10:50 Werner -  Identifying the patients that benefit from CTO PCI
10:50 Werner - Identifying the patients that benefit from CTO PCI
 
12 Valgimigli aimradial20170921 MATRIX program
12 Valgimigli aimradial20170921 MATRIX program12 Valgimigli aimradial20170921 MATRIX program
12 Valgimigli aimradial20170921 MATRIX program
 
Hahalis G - AIMRADIAL 2013 - Ulnar catheterization
Hahalis G - AIMRADIAL 2013 - Ulnar catheterizationHahalis G - AIMRADIAL 2013 - Ulnar catheterization
Hahalis G - AIMRADIAL 2013 - Ulnar catheterization
 
Roberts J - AIMRADIAL 2015 - Ultrasound guidance
Roberts J - AIMRADIAL 2015 - Ultrasound guidanceRoberts J - AIMRADIAL 2015 - Ultrasound guidance
Roberts J - AIMRADIAL 2015 - Ultrasound guidance
 
6_OP_Interventional_Cardiology_Report
6_OP_Interventional_Cardiology_Report6_OP_Interventional_Cardiology_Report
6_OP_Interventional_Cardiology_Report
 
Professional Outcomes PAH 2011-2015 06-01-15
Professional Outcomes PAH 2011-2015 06-01-15Professional Outcomes PAH 2011-2015 06-01-15
Professional Outcomes PAH 2011-2015 06-01-15
 
Statin trials
Statin trials Statin trials
Statin trials
 
Louvard Y - Start radial and advance the skill
Louvard Y - Start radial and advance the skillLouvard Y - Start radial and advance the skill
Louvard Y - Start radial and advance the skill
 
Anaesth audit
Anaesth auditAnaesth audit
Anaesth audit
 

Viewers also liked

Mimicry and amouflage
Mimicry and amouflageMimicry and amouflage
Mimicry and amouflageNick
 
Messa In Sicurezza
Messa In SicurezzaMessa In Sicurezza
Messa In Sicurezza
biccaricambia
 
Biccari Cambia - Presentazione programma elettorale
Biccari Cambia - Presentazione programma elettoraleBiccari Cambia - Presentazione programma elettorale
Biccari Cambia - Presentazione programma elettorale
biccaricambia
 
Ed io pago! - Incontro pubblico sul bilancio
Ed io pago! - Incontro pubblico sul bilancioEd io pago! - Incontro pubblico sul bilancio
Ed io pago! - Incontro pubblico sul bilancio
biccaricambia
 
Graduation2010
Graduation2010Graduation2010
Graduation2010gricer
 
What Do We Mean When We Talk About Content Strategy?
What Do We Mean When We Talk About Content Strategy?What Do We Mean When We Talk About Content Strategy?
What Do We Mean When We Talk About Content Strategy?
Ami Walsh
 
Ciclos de potencia
Ciclos de potenciaCiclos de potencia
Ciclos de potencia
Kust Madera Berrocal
 

Viewers also liked (7)

Mimicry and amouflage
Mimicry and amouflageMimicry and amouflage
Mimicry and amouflage
 
Messa In Sicurezza
Messa In SicurezzaMessa In Sicurezza
Messa In Sicurezza
 
Biccari Cambia - Presentazione programma elettorale
Biccari Cambia - Presentazione programma elettoraleBiccari Cambia - Presentazione programma elettorale
Biccari Cambia - Presentazione programma elettorale
 
Ed io pago! - Incontro pubblico sul bilancio
Ed io pago! - Incontro pubblico sul bilancioEd io pago! - Incontro pubblico sul bilancio
Ed io pago! - Incontro pubblico sul bilancio
 
Graduation2010
Graduation2010Graduation2010
Graduation2010
 
What Do We Mean When We Talk About Content Strategy?
What Do We Mean When We Talk About Content Strategy?What Do We Mean When We Talk About Content Strategy?
What Do We Mean When We Talk About Content Strategy?
 
Ciclos de potencia
Ciclos de potenciaCiclos de potencia
Ciclos de potencia
 

Similar to Singapore OPCABs and AF 2009

Porto I - AIMRADIAL 2014 - Bleeding and events
Porto I - AIMRADIAL 2014 - Bleeding and eventsPorto I - AIMRADIAL 2014 - Bleeding and events
ARTESIA tial - use of apixaban in subclinical atrial fibrillation
ARTESIA tial - use of apixaban in subclinical atrial fibrillationARTESIA tial - use of apixaban in subclinical atrial fibrillation
ARTESIA tial - use of apixaban in subclinical atrial fibrillation
Avishkar Agrawal
 
TAVI 2013: Revisión y perspectivas futuras
TAVI 2013: Revisión y perspectivas futurasTAVI 2013: Revisión y perspectivas futuras
TAVI 2013: Revisión y perspectivas futuras
CardioTeca
 
Kshivets wscts2015
Kshivets wscts2015Kshivets wscts2015
Kshivets wscts2015
Oleg Kshivets
 
Heinz Nixdorf Erbel
Heinz Nixdorf ErbelHeinz Nixdorf Erbel
Heinz Nixdorf Erbel
hospital
 
Carlo Di Mario - Recent Publications & Research in CTO: 2015-16
Carlo Di Mario - Recent Publications & Research in CTO: 2015-16Carlo Di Mario - Recent Publications & Research in CTO: 2015-16
Carlo Di Mario - Recent Publications & Research in CTO: 2015-16
Euro CTO Club
 
Transplanting cardiac amyloidosis when to refer for heart transplant
Transplanting cardiac amyloidosis when to refer for heart transplantTransplanting cardiac amyloidosis when to refer for heart transplant
Transplanting cardiac amyloidosis when to refer for heart transplant
drucsamal
 
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Chaichuk Sergiy
 
Targeted therapy in ovarian cancer
Targeted therapy in ovarian cancerTargeted therapy in ovarian cancer
Targeted therapy in ovarian cancer
Basalama Ali
 
Targeted therapy in ovarian cancer
Targeted therapy in ovarian cancerTargeted therapy in ovarian cancer
Targeted therapy in ovarian cancer
Basalama Ali
 
Triple negative breast cancer-new developments
Triple negative breast cancer-new developmentsTriple negative breast cancer-new developments
Triple negative breast cancer-new developments
NikolaosDiamantopoul1
 
Jnuc 2014 f beygui final
Jnuc 2014 f beygui finalJnuc 2014 f beygui final
Jnuc 2014 f beygui final
Nicolas Peschanski, MD, PhD
 
Ischemia Trial
Ischemia TrialIschemia Trial
Ischemia Trial
Muhammad Sanaan
 
Kshivets astana wscts2017
Kshivets astana wscts2017Kshivets astana wscts2017
Kshivets astana wscts2017
Oleg Kshivets
 
beva in lung cancer.pptx
beva in lung cancer.pptxbeva in lung cancer.pptx
beva in lung cancer.pptx
DoQuyenPhan1
 
Esc np leader oral abs 86477 v13.0 2017 08-25
Esc np leader oral abs 86477 v13.0 2017 08-25Esc np leader oral abs 86477 v13.0 2017 08-25
Esc np leader oral abs 86477 v13.0 2017 08-25
SoM
 
Impact of contralateral carotid or vertebral artery occlusion in patients und...
Impact of contralateral carotid or vertebral artery occlusion in patients und...Impact of contralateral carotid or vertebral artery occlusion in patients und...
Impact of contralateral carotid or vertebral artery occlusion in patients und...
uvcd
 
ACC 2013 what did we learn
ACC 2013 what did we learnACC 2013 what did we learn
ACC 2013 what did we learn
hospital
 
Euro CTO Club – The Euro CTO trial
Euro CTO Club – The Euro CTO trialEuro CTO Club – The Euro CTO trial
Euro CTO Club – The Euro CTO trial
Euro CTO Club
 

Similar to Singapore OPCABs and AF 2009 (20)

Porto I - AIMRADIAL 2014 - Bleeding and events
Porto I - AIMRADIAL 2014 - Bleeding and eventsPorto I - AIMRADIAL 2014 - Bleeding and events
Porto I - AIMRADIAL 2014 - Bleeding and events
 
ARTESIA tial - use of apixaban in subclinical atrial fibrillation
ARTESIA tial - use of apixaban in subclinical atrial fibrillationARTESIA tial - use of apixaban in subclinical atrial fibrillation
ARTESIA tial - use of apixaban in subclinical atrial fibrillation
 
TAVI 2013: Revisión y perspectivas futuras
TAVI 2013: Revisión y perspectivas futurasTAVI 2013: Revisión y perspectivas futuras
TAVI 2013: Revisión y perspectivas futuras
 
Kshivets wscts2015
Kshivets wscts2015Kshivets wscts2015
Kshivets wscts2015
 
Heinz Nixdorf Erbel
Heinz Nixdorf ErbelHeinz Nixdorf Erbel
Heinz Nixdorf Erbel
 
Carlo Di Mario - Recent Publications & Research in CTO: 2015-16
Carlo Di Mario - Recent Publications & Research in CTO: 2015-16Carlo Di Mario - Recent Publications & Research in CTO: 2015-16
Carlo Di Mario - Recent Publications & Research in CTO: 2015-16
 
Transplanting cardiac amyloidosis when to refer for heart transplant
Transplanting cardiac amyloidosis when to refer for heart transplantTransplanting cardiac amyloidosis when to refer for heart transplant
Transplanting cardiac amyloidosis when to refer for heart transplant
 
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
Current Guidelines of Myocardial Revascularisation Patients with Stable Angin...
 
Targeted therapy in ovarian cancer
Targeted therapy in ovarian cancerTargeted therapy in ovarian cancer
Targeted therapy in ovarian cancer
 
Targeted therapy in ovarian cancer
Targeted therapy in ovarian cancerTargeted therapy in ovarian cancer
Targeted therapy in ovarian cancer
 
Triple negative breast cancer-new developments
Triple negative breast cancer-new developmentsTriple negative breast cancer-new developments
Triple negative breast cancer-new developments
 
Jnuc 2014 f beygui final
Jnuc 2014 f beygui finalJnuc 2014 f beygui final
Jnuc 2014 f beygui final
 
Ischemia Trial
Ischemia TrialIschemia Trial
Ischemia Trial
 
S cárdio renal
S cárdio renalS cárdio renal
S cárdio renal
 
Kshivets astana wscts2017
Kshivets astana wscts2017Kshivets astana wscts2017
Kshivets astana wscts2017
 
beva in lung cancer.pptx
beva in lung cancer.pptxbeva in lung cancer.pptx
beva in lung cancer.pptx
 
Esc np leader oral abs 86477 v13.0 2017 08-25
Esc np leader oral abs 86477 v13.0 2017 08-25Esc np leader oral abs 86477 v13.0 2017 08-25
Esc np leader oral abs 86477 v13.0 2017 08-25
 
Impact of contralateral carotid or vertebral artery occlusion in patients und...
Impact of contralateral carotid or vertebral artery occlusion in patients und...Impact of contralateral carotid or vertebral artery occlusion in patients und...
Impact of contralateral carotid or vertebral artery occlusion in patients und...
 
ACC 2013 what did we learn
ACC 2013 what did we learnACC 2013 what did we learn
ACC 2013 what did we learn
 
Euro CTO Club – The Euro CTO trial
Euro CTO Club – The Euro CTO trialEuro CTO Club – The Euro CTO trial
Euro CTO Club – The Euro CTO trial
 

Recently uploaded

Chapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdfChapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdf
Kartik Tiwari
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
Marketing internship report file for MBA
Marketing internship report file for MBAMarketing internship report file for MBA
Marketing internship report file for MBA
gb193092
 
Advantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO PerspectiveAdvantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO Perspective
Krisztián Száraz
 
Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School DistrictPride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
David Douglas School District
 
The Diamond Necklace by Guy De Maupassant.pptx
The Diamond Necklace by Guy De Maupassant.pptxThe Diamond Necklace by Guy De Maupassant.pptx
The Diamond Necklace by Guy De Maupassant.pptx
DhatriParmar
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
deeptiverma2406
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
chanes7
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 

Recently uploaded (20)

Chapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdfChapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdf
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
Marketing internship report file for MBA
Marketing internship report file for MBAMarketing internship report file for MBA
Marketing internship report file for MBA
 
Advantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO PerspectiveAdvantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO Perspective
 
Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School DistrictPride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
 
The Diamond Necklace by Guy De Maupassant.pptx
The Diamond Necklace by Guy De Maupassant.pptxThe Diamond Necklace by Guy De Maupassant.pptx
The Diamond Necklace by Guy De Maupassant.pptx
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 

Singapore OPCABs and AF 2009

  • 1.  
  • 2. AF and OPCABs in our experience Chokchai Suwanakijboriharn Bangkok Heart Hospital Thailand
  • 3.
  • 4.
  • 5.
  • 6. DERMOGRAPHY *0.000 232(76%) 72(28%) Age>70 *0.000 61.6(±10.4) 65.9(± 9.9) Age(mean/SD) NS 197(22%) 35(21%) female NS 728(78%) 135(79%) Male 925 170 Overall CASE P value NO AF AF Parameter
  • 7. Coronary risk factors NS 27(3%) 1(0.6%) Morbid obesity NS 429(46%) 74(46%) Diabetes NS 596(64%) 119(70%) Hypertension Coronary risk factors P value NO AF AF
  • 8. Comorbid NS 37(4%) 9(5%) CVA NS 71(8%) 17(10%) COPD NS 22(2%) 3(2%) PVD NS 34(4%) 9(5%) Renal failure Comorbid P value NO AF AF
  • 9. Risk factors 0.074 67(7%) 6(4%) Cardiogenic shock 0.017 65(7%) 18(11%) Prior PCI Cardiac profile NS 376(42%) 74(45%) Unstable angina NS 332(36%) 63(37%) Left main *0.006 166(18%) 46(27%) CHF NS 268(29%) 46(27%) HX of MI P value NO AF AF
  • 10. Operative factors NS 175(19%) 40(24%) LVEF<40% NS 879(95%) 157(92%) Elective NS 52.5±15.0 50.3±16.1 EF NS 29(3%) 7(4%) Emergency NS 17(2%) 6(4%) Urgency NS 33(4%) 2(1%) Re Do case NS 892(96%) 168(99%) 1 st operation P value NO AF AF
  • 11. Operative factors NS 244(26%) 48(28%) RGA used NS 112(12%) 13(8%) RIMA used NS 270(29%) 47(28%) SVG used NS 95(10%) 19(11%) RRA used NS 644(70%) 117(69%) LRA used NS 870(94%) 158(93%) LIMA used NS 4.17±1.34 4.11±1.38 Graft/patient P value NO AF AF
  • 12. Postoperative results NS 0 1(0.6%) Periop MI NS 5.32±17.3 8.11±28.9 Intubation time (Hr) NS 6(0.6%) 0 Conversion rate NS 4.85±1.29 4.99±1.17 Skin to skin NS 139(15%) 29(17%) IABP P value NO AF AF
  • 13. Postoperative result *0.019 21(2%) 10(6%) Prolong ventilation (Hr) NS 15(2%) 3(2%) Re op bleeding *0.038 8(1%) 5(3%) Postop ARF , dialysis require NS 2(0.2%) 1(0.6%) Permanent stroke P value NO AF AF Parameter
  • 14. Postoperative results NS 43(4.6%) 5(2.9%) Operative mortality *0.004 10.81±9.58 13.65±10.43 LOS *0.001 6(0.6%) 7(4%) Pneumonia NS 1(0.1%) 0 Deep sternal wound infection NS 44(5%) 8(5%) 30 day readmission after procedure P value NO AF AF Parameter
  • 15.
  • 16. Out come between 2 group *0.038 8(1%) 5(3%) Postop ARF , dialysis require 0.017 65(7%) 18(11%) Prior PCI *0.006 166(18%) 46(27%) CHF *0.000 232(76%) 72(28%) Age>70 *0.000 61.6(±10.4) 65.9(± 9.9) Age(mean/SD) P value NO AF AF Parameter
  • 17. Out come between 2 group P value NO AF AF Parameter *0.004 10.81±9.58 13.65±10.43 LOS *0.001 6(0.6%) 7(4%) Pneumonia *0.019 21(2%) 10(6%) Prolong ventilation (Hr)
  • 18. RISK FACTORS INFLUENCING OUTCOME 0.048 1.057 – 3.299 1.867 0.017 Prior PCI or balloon 0.003 1.465-16.485 4.913 0.001 Pneumonia 0.001 1.335 – 3.363 2.119 0.006 CHF 0.003 0.108-0.703 0.275 0.074 Cardiogenic shock 0.000 1.483-3.025 2.118 0.000 Age>70 Multivariate p value 95% confidence interval Relative risk Univariate p value